EUVIMEDEUVIMED entdecken
Multizentrische Studie

Real-World Challenges of Managing Diffuse Large B-Cell Lymphoma in a Developing Country

Raheel Iftikhar iD, Usman Ahmad, Ghulam Haider, Humera Mahmood, Maryam Khan, Misbah Masood, Nida Anwar, Qamar Javed, Nadia Sajid, Rija Tariq, Sana Mehmod, Javeria Haider und 7 weitere

JCO Global Oncology · 2024

DOI: 10.1200/go.23.00386 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift JCO Global Oncology, 2024. Verfasst von Raheel Iftikhar und 18 weiteren Autor:innen. Beteiligte Einrichtung: Armed Forces Bone Marrow Transplant Center, Rawalpindi, Pakistan. Hauptthemen laut MEDLINE: Developing Countries, Lymphoma, Large B-Cell, Diffuse. Die Arbeit nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE To highlight challenges and cancer care disparities in patients of diffuse large B-cell lymphoma management in resource-constrained settings. MATERIALS AND METHODS This multicenter retrospective study included 738 patients from 12 public and private sector hematology-oncology centers across Pakistan. Patients were divided into limited-resource and enhanced-resource settings as per national diffuse large B-cell lymphoma (DLBCL) guidelines. RESULTS The median age at diagnosis was 47 years (range, 14-89). Male:female ratio was 2.5:1. Majority of the patients (69.3%) were treated in limited-resource settings. Computed tomography was used as a staging modality in 442 (60%) patients. Limited-stage DLBCL was present in 13.5% of patients, while 86.3% had advanced-stage disease at diagnosis. First-line regimens included rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in 56% and cyclophosphamide, doxorubicin, vincristine, prednisone in 34% of patients, while 10% of patients received palliative regimens upfront. Of evaluable data, complete remission was documented in 299 (74.4%) patients, 39 (9.8%) had partial response and 63 (13.5%) had progressive disease. Disease-free survival (DFS) and overall survival (OS) status were not available for 345 (46.8%) patients at the time of data collection. Overall study cohort had a median follow-up of 2.2 years with a median OS of 3.6 years (95% CI, 3.1 to 4.1), median DFS of 3.1 years (95% CI, 2.6 to 3.6), and a 5-year OS of 40% and DFS of 36%. CONCLUSION Patients from low- and middle-income countries present at an earlier age and have more advanced disease. Patients were frequently lost to follow-up, and record keeping was inadequate more so in patients treated in limited-resource settings. There is a need to establish a national lymphoma registry, improve record keeping, and standardize treatments to ensure improvement in treatment outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Developing CountriesLymphoma, Large B-Cell, DiffuseHumansMaleFemaleAdolescentYoung AdultAdultMiddle AgedAgedAged, 80 and overVincristinePrednisoneRetrospective StudiesAntineoplastic Combined Chemotherapy ProtocolsCyclophosphamideDoxorubicin

Substanzen

VincristinePrednisoneCyclophosphamideDoxorubicin

Autor:innen und Institutionen

  • Armed Forces Bone Marrow Transplant Center, Rawalpindi, Pakistan.
  • Shoukat Khanam Memorial Cancer Hospital and Research Center, Lahore, Pakistan.
  • Jinnah Post Graduate Medical Centre, Karachi, Pakistan.
  • Nuclear Medicine, Oncology and Radiotherapy Institute, Rawalpindi, Pakistan.
  • Institute of Nuclear Medicine and Oncology, Lahore, Pakistan.
  • National Institute of Blood Disease & Bone Marrow Transplantation, Karachi, Pakistan.

ORCID-Profile: Raheel Iftikhar, Munira Moosajee, Zeba Aziz

Zitieren

APA

Iftikhar, R., Ahmad, U., Haider, G., Mahmood, H., Khan, M., Masood, M., Anwar, N., Javed, Q., Sajid, N., Tariq, R., Mehmod, S., Haider, J., Abro, N. A., Shahbaz, S., Khokhar, A., Khan, Z. A., Pervez, H., Moosajee, M., & Aziz, Z. (2024). Real-World Challenges of Managing Diffuse Large B-Cell Lymphoma in a Developing Country. JCO Global Oncology. https://doi.org/10.1200/go.23.00386

Vancouver

Iftikhar R, Ahmad U, Haider G, Mahmood H, Khan M, Masood M, et al. Real-World Challenges of Managing Diffuse Large B-Cell Lymphoma in a Developing Country. JCO Global Oncology. 2024. doi:10.1200/go.23.00386

BibTeX
@article{Iftikhar2024,
  author = {Iftikhar, Raheel and Ahmad, Usman and Haider, Ghulam and Mahmood, Humera and Khan, Maryam and Masood, Misbah and Anwar, Nida and Javed, Qamar and Sajid, Nadia and Tariq, Rija and Mehmod, Sana and Haider, Javeria and Abro, Nargis Aalam and Shahbaz, Shanzah and Khokhar, Abbas and Khan, Zeeshan Ahmed and Pervez, Hassan and Moosajee, Munira and Aziz, Zeba},
  title = {Real-World Challenges of Managing Diffuse Large B-Cell Lymphoma in a Developing Country},
  journal = {JCO Global Oncology},
  year = {2024},
  doi = {10.1200/go.23.00386}
}
Kostenlos starten →